Brief: Annovis Bio Announces Approval For European Union Clinical Trial Sites For Phase 3 Study Of Parkinson's Disease Drug Buntanetap
08/02/2023 12:47
Feb 8 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO ANNOUNCES APPROVAL FOR EUROPEAN UNION CLINICAL
TRIAL
SITES FOR THE PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF
PARKINSON'S DISEASE
* ANNOVIS BIO INC - COMPANY WAS GRANTED APPROVAL FOR AN
ADDITIONAL
48 SITES ACROSS FIVE EUROPEAN UNION COUNTRIES
* ANNOVIS BIO INC - ANTICIPATES HAVING SUFFICIENT NUMBER OF
PATIENTS WHO HAVE RECEIVED TWO MONTHS OF THERAPY TO CONDUCT
INTERIM ANALYSIS IN Q2 OF 2023
Source text for Eikon: ID:nPn3LpgkBa
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman